NEW YORK (Reuters Health)—An adherent-invasive E. coli pathotype present in the bowel may contribute to the development of Crohn’s disease-associated spondyloarthritis, researchers say. “Clinical symptoms, including extra-intestinal manifestations, in Crohn’s disease offer a portal into the microbial, immune, and genetic mechanisms underlying disease pathogenesis,” Dr. Randy S. Longman from Weill Cornell Medical College in New…
Articles by Natasha Yetman
Prescription-Drug Monitoring Cuts Doctor-Shopping for Painkillers
(Reuters Health)—State programs that require physicians to check drug registries before writing prescriptions appeared to slash the odds of doctor-shopping for opioid pain relievers, a new study found. “Our study shows that prescription-drug monitoring programs are a promising component of a multifaceted strategy to address the opioid epidemic,” Ryan Mutter, one of the study authors,…
UnitedHealth Sued by U.S. Over Medicare Charges
(Reuters) – The U.S. Department of Justice (DOJ) has joined a whistleblower lawsuit against UnitedHealth Group Inc. that claims the country’s largest health insurer and its units and affiliates overcharged Medicare hundreds of millions of dollars, a law firm representing the whistleblower said on Thursday. “We reject these more than five-year-old claims and will contest…
Intraocular Vancomycin Associated with Hemorrhagic Occlusive Retinal Vasculitis
NEW YORK (Reuters Health)—Intraocular vancomycin may lead to potentially blinding hemorrhagic occlusive retinal vasculitis (HORV), a new study suggests. “The importance of this study was to present in a number of patients overwhelming evidence that rarely, intraocular vancomycin is associated with sight-threatening retinal vascular occlusion,” says lead author Dr. Andre J. Witkin of Tufts Medical…
FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
(Reuters)—The U.S. Food and Drug Administration has approved Valeant Pharmaceuticals International Inc.’s brodalumab (Siliq) to treat adults with moderate to severe plaque psoriasis. Brodalumab is administered as an injection. Brodalumab is intended for patients who are candidates for systemic therapy or phototherapy and have failed to respond, or have stopped responding to other systemic therapies,…
Don’t Reach for Pills for Most Chronic Low Back Pain
(Reuters Health)—People should try non-drug treatment options like massage or stretching for most cases of chronic low back pain before choosing treatment with over-the-counter or prescription drugs, according to new guidelines from the American College of Physicians (ACP). If the pain began recently, the guidelines recommend superficial heat, massage, acupuncture or spinal manipulation. If patients…
Review Finds Increased Osteoarthritis Risk in Tactical Athletes
NEW YORK (Reuters Health)—Members of the military and firefighters are at increased risk of osteoarthritis (OA), a new systematic review shows. “Osteoarthritis is more common in people who are tactical athletes, people who are firefighters and military service members, than it is in the general population,” Dr. Kenneth Cameron of Keller Army Hospital in West…
Two U.S. Lawmakers Probe Marathon over $89,000 Drug Price
WASHINGTON (Reuters)—Two U.S. lawmakers have called on privately held Marathon Pharmaceuticals LLC to explain how it came to price its newly approved drug to treat Duchenne muscular dystrophy at $89,000 a year when patients have for decades been able to acquire it overseas for as little as $1,000. The drug, Emflaza, known generically as deflazacort,…
U.S. Senate Confirms Rep. Price as Health Secretary
WASHINGTON (Reuters) – The U.S. Senate voted on Friday to confirm Rep. Tom Price (R-Ga.) as the top U.S. healthcare official, putting a determined opponent of Obamacare in position to help President Donald Trump dismantle the healthcare law. The Senate voted 52-47 to approve the conservative congressman and orthopedic surgeon as secretary of the Department…
U.S. Senators Question Kaleo’s $4,500 tag on Opioid Overdose Treatment
(Reuters)—U.S. Sen. Claire McCaskill (D-Mo.) on Thursday asked Kaleo Pharmaceuticals to justify the more than 550% surge in the price of its device to treat opioid overdoses, becoming the second senator to question Evzio’s $4,500 price tag. Evzio contains the overdose-reversing drug naloxone and can be used in emergencies by people without medical training. Privately…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 97
- Next Page »